Modern management of juvenile myoclonic epilepsy.

Abstract:

:Juvenile myoclonic epilepsy (JME) is a common genetic epilepsy syndrome usually presenting in adolescence and characterized by myoclonic jerks, predominately in the arms, associated with tonic-clonic seizures and less often generalized absences. Although the evidence base for treating JME is weak, most experts regard sodium valproate as drug of first choice. The recent diktat from the European regulatory agency - recommending that sodium valproate should not be prescribed to female children, adolescents or women of childbearing potential unless other treatments were ineffective or not tolerated - has substantially changed the way JME is being managed in this population. This paper reviews the literature underpinning the pharmacological treatment of JME. Data reporting associated symptoms of frontal lobe dysfunction in some patients with JME are discussed, as is the importance of counselling on lifestyle issues as an essential component of management. Long-term studies examining pharmacological and quality-of-life outcomes are reviewed, indicating a range of different phenotypes and likely genotypes underpinning this fascinating disorder. Lastly, a practical approach to managing JME in young men and women is summarized.

journal_name

Expert Rev Neurother

authors

Brodie MJ

doi

10.1080/14737175.2016.1179113

subject

Has Abstract

pub_date

2016-06-01 00:00:00

pages

681-8

issue

6

eissn

1473-7175

issn

1744-8360

journal_volume

16

pub_type

杂志文章,评审
  • Update on therapies for cluster headache.

    abstract::Cluster headache is one of the primary headache disorders. It is considered the most severe headache syndrome known to humans. In most instances, this disorder is readily treatable when the correct medications are utilized at the correct dosages. Cluster headache treatment involves abortive, transitional and preventiv...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.3.295

    authors: Rozen TD

    更新日期:2002-05-01 00:00:00

  • Therapeutic options for cervicogenic headache.

    abstract::The term cervicogenic headache (CeH) describes a syndrome originating from the cervical spine. There are a variety of therapeutic approaches used for the management of CeH, but scientific evidence of their effectiveness is scarce. No medication drug has proven to be effective. The evidence for greater occipital nerve ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.863710

    authors: Fernández-de-las-Peñas C,Cuadrado ML

    更新日期:2014-01-01 00:00:00

  • Translational pain biomarkers in the early development of new neurotherapeutics for pain management.

    abstract::Translation of the analgesic efficacy of investigational neurotherapeutics from pre-clinical pain models into clinical trial phases is associated with a high risk of failure. Application of human pain biomarkers in early stages of clinical trials can potentially enhance the rate of successful translation, which would ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.884925

    authors: Arendt-Nielsen L,Nielsen TA,Gazerani P

    更新日期:2014-03-01 00:00:00

  • Advances in understanding spontaneous intracerebral hemorrhage: insights from neuroimaging.

    abstract::Spontaneous (non-traumatic) symptomatic intracerebral hemorrhage is a devastating form of stroke, with very high overall mortality and morbidity. Even with the best current medical or surgical treatment, outcomes still remain poor. By contrast with ischemic stroke, the incidence of intracerebral hemorrhage is not decr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.918506

    authors: Wilson D,Charidimou A,Werring DJ

    更新日期:2014-06-01 00:00:00

  • Almotriptan: a review of 20 years' clinical experience.

    abstract::Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of A...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1591951

    authors: Pascual J,Vila C

    更新日期:2019-08-01 00:00:00

  • Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.

    abstract::Clomipramine ushered in a new age of pharmacotherapy for obsessive-compulsive disorders, and it also facilitated our understanding of the biological aspects of obsessive-compulsive disorder, focusing on the serotonergic systems. The introduction of selective serotonin reuptake inhibitors has led to great progress in t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.7.945

    authors: Kamijima K,Aoki M

    更新日期:2006-07-01 00:00:00

  • Brivaracetam efficacy and safety in focal epilepsy.

    abstract::Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1631160

    authors: Makke Y,Abou-Khalil B

    更新日期:2019-10-01 00:00:00

  • The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder.

    abstract::Pharmacotherapy, psychotherapy and other nonpharmacological interventions are used in patients with major depressive disorder (MDD). However, 50% of the patients with MDD fail to achieve a response to first-line antidepressant treatment. In four of five acute monotherapy studies, once-daily extended-release quetiapine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.846520

    authors: Weisler R,McIntyre RS

    更新日期:2013-11-01 00:00:00

  • An update on the recognition and treatment of non-convulsive status epilepticus in the intensive care unit.

    abstract:INTRODUCTION:Non-convulsive status epilepticus (NCSE) is a complex and diverse condition which is often an under-recognised entity in the intensive care unit. When NCSE is identified the optimal treatment strategy is not always clear. Areas covered: This review is based on a literature review of the key literature in t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1369880

    authors: Kinney MO,Kaplan PW

    更新日期:2017-10-01 00:00:00

  • Genome-wide investigation of rare structural variants identifies VIPR2 as a new candidate gene for schizophrenia.

    abstract::Research has shown that structural variation in the human genome, including rare copy number variations (CNVs), contributes to genetic susceptibility to psychiatric diseases, such as schizophrenia, a devastating complex disorder with a high genetic load. The study by Vacic et al. applied a genome-wide approach to dete...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.84

    authors: Nieratschker V,Meyer-Lindenberg A,Witt SH

    更新日期:2011-07-01 00:00:00

  • Rivastigmine for Alzheimer's disease.

    abstract::Alzheimer's disease is the most common form of neurodegenerative dementia and poses considerable health challenges to both patients and their families. Rivastigmine is a powerful slow-reversible, noncompetitive carbamate cholinesterase inhibitor that is approved for the treatment of mild-to-moderate Alzheimer's diseas...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.5.563

    authors: Desai AK,Grossberg GT

    更新日期:2005-09-01 00:00:00

  • Fear reduction in patients with chronic pain: a learning theory perspective.

    abstract::Acute pain informs the individual that there is an imminent threat of body damage, and is associated with the urge to escape and avoid. Fear learning takes place when neutral stimuli receive the propensity to predict the occurrence of pain, and when defensive responses are initiated in anticipation of potential threat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.115

    authors: den Hollander M,de Jong JR,Volders S,Goossens ME,Smeets RJ,Vlaeyen JW

    更新日期:2010-11-01 00:00:00

  • Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.

    abstract::Alzheimer's disease (AD) is a prevalent and currently incurable brain disease whose impact will continue to rise as the population ages. With limited treatment options, a variety of experimental therapies are currently in clinical trials. EVP-6124 (encenicline) is an α7 nicotinic acetylcholine receptor partial agonist...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.995639

    authors: Deardorff WJ,Shobassy A,Grossberg GT

    更新日期:2015-01-01 00:00:00

  • Trigeminal neuralgia and persistent idiopathic facial pain.

    abstract::Trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are two of the most puzzling orofacial pain conditions and affected patients are often very difficult to treat. TN is characterized by paroxysms of brief but severe pain followed by asymptomatic periods without pain. In some patients a constant dul...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.156

    authors: Obermann M,Holle D,Katsarava Z

    更新日期:2011-11-01 00:00:00

  • Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring.

    abstract:INTRODUCTION:Neurodegenerative processes occur from the beginning of multiple sclerosis, contribute to irreversible clinical disability and are only partially addressed by current disease-modifying therapies. Reliable quantification of neuro-axonal damage may contribute to improve the assessment of disease activity and...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1760846

    authors: Preziosa P,Rocca MA,Filippi M

    更新日期:2020-08-01 00:00:00

  • Post-traumatic headache.

    abstract::Post-traumatic headache (PTH) is a very controversial disorder, particularly when it comes to chronic PTH following mild closed head injury and headache attributed to whiplash injury. Nevertheless, mild traumatic brain injury is very common in Western societies, affecting approximately 1.8 million individuals in the U...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.84

    authors: Obermann M,Holle D,Katsarava Z

    更新日期:2009-09-01 00:00:00

  • New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention.

    abstract:INTRODUCTION:Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleedin...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1268053

    authors: Arnao V,Riolo M,Tuttolomondo A,Pinto A,Fierro B,Aridon P

    更新日期:2017-06-01 00:00:00

  • Precision medicine in genetic epilepsies: break of dawn?

    abstract:INTRODUCTION:Therapy with current antiepileptic drugs aims at reducing the likelihood of seizure occurrence rather than influencing the underlying disease process. Therefore, antiepileptic drugs have an anticonvulsant rather than antiepileptic property. Areas covered: The increasing identification of genetic causes for...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1253476

    authors: Reif PS,Tsai MH,Helbig I,Rosenow F,Klein KM

    更新日期:2017-04-01 00:00:00

  • Alzheimer's disease: review of current nanotechnological therapeutic strategies.

    abstract::Introduction: Alzheimer's Disease (AD) is a progressive neurodegenerative pathology characterized by the presence of neuritic plaques and neurofibrillary tangles. The most important markers in AD pathology include excessive accumulation of amyloid beta (Aβ42) and phosphorylated tau (P-tau) proteins. One of the possibl...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1719069

    authors: Baranowska-Wójcik E,Szwajgier D

    更新日期:2020-03-01 00:00:00

  • The role of electroencephalogram in neonatal seizure detection.

    abstract:INTRODUCTION:The role of EEG in neonatal seizure detection is well-established, being the multichannel video-EEG the gold standard. However, in the clinical practice often amplitude integrated EEG (aEEG) is used, in order to overcome the difficulties related to EEG use. Areas covered: An overview regarding neonatal sei...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2018.1413352

    authors: Pisani F,Pavlidis E

    更新日期:2018-02-01 00:00:00

  • Emotional dysregulation in adult ADHD: What is the empirical evidence?

    abstract::Attention deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder characterized by symptoms of inattention, hyperactivity and impulsivity. There is an ongoing discussion whether symptoms of emotional dysregulation should be added to the conceptualization of ADHD in order to describe the psychopathology ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.109

    authors: Retz W,Stieglitz RD,Corbisiero S,Retz-Junginger P,Rösler M

    更新日期:2012-10-01 00:00:00

  • Post-stroke pain.

    abstract::Pain is one of the most troublesome sequelae of stroke, occurring in 19-74% of patients. A portion of this post-stroke pain is caused by the brain lesion itself; this is called 'central post-stroke pain' (CPSP). Although the prevalence of CPSP among stroke patients is low (1-8%), the persistent, often treatment-refrac...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.19

    authors: Kim JS

    更新日期:2009-05-01 00:00:00

  • Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

    abstract:INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1326818

    authors: Khan A,Corbett A,Ballard C

    更新日期:2017-07-01 00:00:00

  • Cannabinoids as potential new therapy for the treatment of gliomas.

    abstract::Gliomas constitute the most frequent and malignant primary brain tumors. Current standard therapeutic strategies (surgery, radiotherapy and chemotherapeutics, e.g., temozolomide, carmustin or carboplatin) for their treatment are only palliative and survival diagnosis is normally 6-12 months. The development of new the...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.1.37

    authors: Parolaro D,Massi P

    更新日期:2008-01-01 00:00:00

  • CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine.

    abstract::Cortical spreading depression (CSD) has been at the center stage of migraine pathophysiology for approximately six decades. Reanalysis of CSD reveals several major unbridgeable gaps in this experimental neurophysiologic concept for migraine. Key phenotypic and pharmacological features of migraine challenge the assumed...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.103

    authors: Gupta VK

    更新日期:2009-11-01 00:00:00

  • Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.

    abstract::Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative disorder, causes cognitive decline and has a devastating effect on the quality of life. AD occurs mainly through abnormal amyloid β peptide (Aβ) and tau protein (tau) activity around/in neurons. Aβ-based therapeutic techniques have been s...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1621750

    authors: Kuo YC,Rajesh R

    更新日期:2019-07-01 00:00:00

  • Risk factors for schizophrenia.

    abstract::Over the last decade, much progress has been made towards identifying risk factors for schizophrenia. It is now thought that many genes of small effect contribute towards risk of developing schizophrenia and some of these probably confer susceptibility to environmental factors. Large population-based studies, using re...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.1.2.183

    authors: Boydell J

    更新日期:2001-11-01 00:00:00

  • Pharmacological treatment of trigeminal neuralgia.

    abstract:INTRODUCTION:Unique among the different neuropathic pain conditions, trigeminal neuralgia frequently has an excellent response to some selected drugs, which, on the other hand, often entail disabling side effects. Physicians should be therefore acquainted with the management of these drugs and the few alternative optio...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1370375

    authors: Di Stefano G,Truini A

    更新日期:2017-10-01 00:00:00

  • Role of the cholinergic system in the pathology and treatment of schizophrenia.

    abstract::Schizophrenia is a devastating psychiatric disorder; the diagnosis probably encompasses a number of illnesses with similar clinical presentations, complicating both treatment and studies into the pathology of the disorder. The development of antipsychotic medications revolutionized treatment for the disorder. However,...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.9.1.73

    authors: Scarr E,Dean B

    更新日期:2009-01-01 00:00:00

  • Update on the treatment of vitamin B6 dependent epilepsies.

    abstract::Introduction: Vitamin B6 dependent epilepsies are a group of treatable diseases (ALDH7A1 deficiency, PNPO deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia and glycosylphosphatidylinositol anchor synthesis defects) responding to pyridoxine or pyridoxal-5I-phosphate. Areas covere...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1648212

    authors: Mastrangelo M,Cesario S

    更新日期:2019-11-01 00:00:00